Indi Molecular, Inc.

Indi Molecular, Inc. is a biotechnology company focused on developing innovative synthetic small molecule oncology therapeutics to improve cancer treatment outcomes. Founded in 2013 and headquartered in Culver City, US, Indi Molecular specializes in oncology therapeutics. The company has undergone strategic developments but has not reported significant pivots.

It raised USD 11. 5 mn in Series A funding on June 28, 2017, from prominent investors including Asset Management Ventures, Legend Capital, and Sabey Corporation. Albert Luderer serves as CEO, leading the company’s efforts in the oncology field. Indi Molecular specializes in the development of synthetic small molecule oncology therapeutics, notably targeting overexpressed folate receptors in ovarian cancer and KRAS G12D-expressing pancreatic cancers.

Their primary offering includes Protein Catalyzed Capture (PCC) agents, engineered as peptide replacements for traditional antibody-based therapeutics. The PCC technology enables the creation of small peptides that exhibit pico-molar to low nano-molar binding affinities with enhanced cooperative binding, significantly improving therapeutic effectiveness. The company’s products are designed for efficient synthesis and robust manufacturing utilizing fully synthetic D-amino acids, which enhance stability and solubility while ensuring renal clearance. Indi Molecular targets a range of healthcare providers and research institutions within the oncology field, focusing on markets in North America, Europe, and Asia.

Indi Molecular generates revenue through the sale of its proprietary PCC agents to pharmaceutical companies, research institutions, and biotechnology firms engaged in oncology therapeutics. The company operates under a business-to-business (B2B) model, allowing clients to access its products through direct purchases or strategic partnerships. Transactions often involve contractual agreements detailing specific delivery timelines and performance metrics associated with the PCC agents. Pricing is aligned with the value these agents provide in advanced cancer treatment, incorporating factors such as binding affinity and therapeutic efficacy, positioning Indi Molecular’s offerings as innovative solutions in the oncology market.

Indi Molecular plans to utilize the USD 11. 5 mn raised in its Series A funding to support the development of new products and expand into additional markets. The company is focusing on upcoming PCC agents designed to enhance therapeutic efficacy in oncology, with targeted releases anticipated in the near term. Plans include geographical expansion into Europe and Asia by 2025, aiming to establish strategic partnerships with local healthcare providers and research institutions.